There are 2789 resources available
616P - Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Presenter: Daniel George
Session: ePoster Display
617P - Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project
Presenter: Taigo Kato
Session: ePoster Display
618P - Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
Presenter: John Shen
Session: ePoster Display
619P - Immune profiling of advanced prostate cancer harbouring homologous recombination deficiency
Presenter: Maryam Soleimani
Session: ePoster Display
541P - Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with previously treated advanced solid tumours
Presenter: Maen Hussein
Session: ePoster Display
542P - Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours
Presenter: Manish Patel
Session: ePoster Display
543P - Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Presenter: Mark Lythgoe
Session: ePoster Display
544P - A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Presenter: Eunjung Lee
Session: ePoster Display
545P - First-in-human (FIH) study of E7130 in patients (pts) with advanced solid tumors: Primary result of dose-escalation part
Presenter: Toshihiko Doi
Session: ePoster Display